Dutch Hospital Resumes Own Manufacture Of Leadiant’s Costly Drug
Aims To Address Steep Price Rise That Impairs Patient Access
Executive Summary
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.